<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="9862">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05688618</url>
  </required_header>
  <id_info>
    <org_study_id>CEI-004-20160729</org_study_id>
    <nct_id>NCT05688618</nct_id>
  </id_info>
  <brief_title>Effect of the Administration of a Symbiotic (E. Faecium and Agave Inulin) on Mild Cognitive Impairment in Older Adults</brief_title>
  <official_title>Effect of the Administration of a Symbiotic (E. Faecium and Agave Inulin) on Mild Cognitive Impairment in Older Adults</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Anahuac University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Anahuac University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Cognitive impairment is one of the fastest growing diseases in the last decades, given the&#xD;
      significant increase in senior citizen population in Mexico and the world.&#xD;
&#xD;
      Several studies have discussed the gut-microbiota-brain axis. It has been demonstrated that a&#xD;
      balanced gut microbiota, prevents an increase in pro-inflammatory cytokines that affect&#xD;
      specific brain areas; having an important impact at the cortical level of the hippocampus&#xD;
      which translates to diminished cognitive function and the start of cognitive impairment&#xD;
      symptoms.&#xD;
&#xD;
      After multiple studies on the effect of the administration of symbiotics in animal models in&#xD;
      cognition and memory, there have been positive results, observing improvement in cognition&#xD;
      and decrement in inflammatory cytokines at hippocampus level.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Cognitive impairment is one of the fastest growing diseases in the last decades, given the&#xD;
      significant increase in senior citizen population in Mexico and the world.&#xD;
&#xD;
      Cognitive impairment is the loss of cognitive functions, in the abscence of other pathologies&#xD;
      that may be the cause of the memory loss. It is well known that this pathology can progress&#xD;
      to more severe states reaching irreversible dementia such as Alzheimer in a short period of&#xD;
      approximately 5 years from the onset of the disease.&#xD;
&#xD;
      Given the rapid increase in incidence of cognitive impairment, there have been several&#xD;
      studies on the management of symptoms and on the natural course of the disease.&#xD;
&#xD;
      Several studies have discussed the gut-microbiota-brain axis. It has been demonstrated that a&#xD;
      balanced gut microbiota, prevents an increase in pro-inflammatory cytokines that affect&#xD;
      specific brain areas; having an important impact at the cortical level of the hippocampus&#xD;
      which translates to diminished cognitive function and the start of cognitive impairment&#xD;
      symptoms.&#xD;
&#xD;
      After multiple studies on the effect of the administration of symbiotics in animal models in&#xD;
      cognition and memory, there have been positive results, observing improvement in cognition&#xD;
      and decrement in inflammatory cytokines at hippocampus level.&#xD;
&#xD;
      The objective of this study is to evaluate the effect of the symbiotic on the cognitive&#xD;
      process in senior adults.&#xD;
&#xD;
      To achieve this a clinical trial will be held in a senior citizen population who will be&#xD;
      administered a symbiotic compound (enterococcus faecium and inulin) for 8 weeks and evaluated&#xD;
      for cognitive functions using Mini-mental state examination, rey-osterrieth complex, and a&#xD;
      validated tool (AeRAC).&#xD;
&#xD;
      The variables will be expressed as mean ± standard deviation, depending on the type of&#xD;
      distribution of the data. It will be used paired T Student for homogenous data in an&#xD;
      intragroup comparison or Wilcoxon test for heterogenous data. For intergroup comparison it&#xD;
      will be used independent T Student for homogenous data and U Mann Whitney for dependent group&#xD;
      in heterogenous data. Data analysis will be carried out using the latest version of GraphPad&#xD;
      Prism.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 16, 2023</start_date>
  <completion_date type="Anticipated">May 20, 2023</completion_date>
  <primary_completion_date type="Anticipated">May 20, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Care Provider, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cognitive impairment</measure>
    <time_frame>8 weeks</time_frame>
    <description>Change in Score for Mini mental state examination</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cognitive impairment</measure>
    <time_frame>8 weeks</time_frame>
    <description>Change in Score for Rey-Osterrieth complex figure</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cognitive impairment</measure>
    <time_frame>8 weeks</time_frame>
    <description>Change in Score for AeRAC (Instrumento de expectativas de autoeficacia)</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">48</enrollment>
  <condition>Cognitive Impairment</condition>
  <arm_group>
    <arm_group_label>Experimental group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Enteroccocus Facieum and Agave Inulin</intervention_name>
    <description>A pack of symbiotic powder with 1 gram of e. facieum and 8g of agave inulin will be administered daily for 8 weeks</description>
    <arm_group_label>Experimental group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>A pack of unsweetened almond powder milk will be administered daily for 8 weeks</description>
    <arm_group_label>Control group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with mild cognitive impairment&#xD;
&#xD;
          -  Patients who sign the informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients who do not have mild cognitive impairment&#xD;
&#xD;
          -  Patients with advanced cognitive impairment such as Alzheimers disease&#xD;
&#xD;
          -  Patients with comorbidities that influence the cognitive functions such as diabetes&#xD;
             mellitus, cerebral ischemia or previous brain trauma&#xD;
&#xD;
          -  Patients who do not sign the informed consent&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>70 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>JOSE JUAN ANTONIO IBARRA ARIAS, MEDICO CIRUJANO</last_name>
    <phone>5554197603</phone>
    <email>jose.ibarra@anahuac.mx</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>ADELA ESCANDON CESARMAN, MEDICO CIRUJANO</last_name>
    <phone>5520459938</phone>
    <email>adela.escandon.cesarman@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hospital ABC Santa Fe</name>
      <address>
        <city>Ciudad de Mexico</city>
        <zip>05300</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Adela Escandon-Cesarman, Medical degree</last_name>
      <phone>5520459938</phone>
      <email>adela.escandon.cesarman@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Mexico</country>
  </location_countries>
  <link>
    <url>https://www.who.int/es/news-room/fact-sheets/detail/dementia</url>
    <description>Related Info</description>
  </link>
  <link>
    <url>https://doi.org/10.3389/fmicb.2018.01791</url>
    <description>Related Info</description>
  </link>
  <link>
    <url>http://www.conapo.gob.mx/work/models/CONAPO/Resource/1529/2/images/DocumentoMetodologicoProyecciones2010_2050.pdf</url>
    <description>Related Info</description>
  </link>
  <reference>
    <citation>Borras Blasco C, Vina Ribes J. [Neurophysiology and ageing. Definition and pathophysiological foundations of cognitive impairment]. Rev Esp Geriatr Gerontol. 2016 Jun;51 Suppl 1:3-6. doi: 10.1016/S0211-139X(16)30136-6. Spanish.</citation>
    <PMID>27719970</PMID>
  </reference>
  <reference>
    <citation>Benavides-Caro, C. Deterioro cognitivo en el adulto mayor. Medigraphic, (2017). 40(2).</citation>
  </reference>
  <reference>
    <citation>Romo-Araiza A, Gutierrez-Salmean G, Galvan EJ, Hernandez-Frausto M, Herrera-Lopez G, Romo-Parra H, Garcia-Contreras V, Fernandez-Presas AM, Jasso-Chavez R, Borlongan CV, Ibarra A. Probiotics and Prebiotics as a Therapeutic Strategy to Improve Memory in a Model of Middle-Aged Rats. Front Aging Neurosci. 2018 Dec 18;10:416. doi: 10.3389/fnagi.2018.00416. eCollection 2018.</citation>
    <PMID>30618722</PMID>
  </reference>
  <reference>
    <citation>Landefeld, C. Current geriatric diagnosis &amp; treatment. New York: McGraw-Hill Professional. (2004).</citation>
  </reference>
  <reference>
    <citation>Lin JS, O'Connor E, Rossom RC, Perdue LA, Eckstrom E. Screening for cognitive impairment in older adults: A systematic review for the U.S. Preventive Services Task Force. Ann Intern Med. 2013 Nov 5;159(9):601-12. doi: 10.7326/0003-4819-159-9-201311050-00730. Erratum In: Ann Intern Med. 2014 Jan 7;160(1):72.</citation>
    <PMID>24145578</PMID>
  </reference>
  <reference>
    <citation>Grammas P. Neurovascular dysfunction, inflammation and endothelial activation: implications for the pathogenesis of Alzheimer's disease. J Neuroinflammation. 2011 Mar 25;8:26. doi: 10.1186/1742-2094-8-26.</citation>
    <PMID>21439035</PMID>
  </reference>
  <reference>
    <citation>Ticinesi A, Tana C, Nouvenne A, Prati B, Lauretani F, Meschi T. Gut microbiota, cognitive frailty and dementia in older individuals: a systematic review. Clin Interv Aging. 2018 Aug 29;13:1497-1511. doi: 10.2147/CIA.S139163. eCollection 2018.</citation>
    <PMID>30214170</PMID>
  </reference>
  <reference>
    <citation>Novotny M, Klimova B, Valis M. Microbiome and Cognitive Impairment: Can Any Diets Influence Learning Processes in a Positive Way? Front Aging Neurosci. 2019 Jun 28;11:170. doi: 10.3389/fnagi.2019.00170. eCollection 2019.</citation>
    <PMID>31316375</PMID>
  </reference>
  <reference>
    <citation>Dalile, B., Verbeke, K., Van Oudenhove, L. and Vervliet, B. Nourishing the gut microbiota: The potential of prebiotics in microbiota-gut-brain axis research. Behavioral and Brain Sciences, (2019). 42.</citation>
  </reference>
  <reference>
    <citation>Quigley EM. Prebiotics and probiotics; modifying and mining the microbiota. Pharmacol Res. 2010 Mar;61(3):213-8. doi: 10.1016/j.phrs.2010.01.004. Epub 2010 Jan 18.</citation>
    <PMID>20080184</PMID>
  </reference>
  <reference>
    <citation>Olveira G, Gonzalez-Molero I. An update on probiotics, prebiotics and symbiotics in clinical nutrition. Endocrinol Nutr. 2016 Nov;63(9):482-494. doi: 10.1016/j.endonu.2016.07.006. Epub 2016 Sep 12. English, Spanish.</citation>
    <PMID>27633133</PMID>
  </reference>
  <reference>
    <citation>Bautista Justo, M.; García Oropeza, L.; Salcedo Hernández, R.; Parra Negrete, L. A. Azúcares en agaves (agave tequilana Weber) cultivados en el estado de guanajuato Acta Universitaria, vol. 11, núm. 1, abril, 2001, pp. 33-38</citation>
  </reference>
  <reference>
    <citation>Louzada ER, Ribeiro SML. Synbiotic supplementation, systemic inflammation, and symptoms of brain disorders in elders: A secondary study from a randomized clinical trial. Nutr Neurosci. 2020 Feb;23(2):93-100. doi: 10.1080/1028415X.2018.1477349. Epub 2018 May 23.</citation>
    <PMID>29788823</PMID>
  </reference>
  <reference>
    <citation>Ginsberg TB, Powell L, Emrani S, Wasserman V, Higgins S, Chopra A, Cavalieri TA, Libon DJ. Instrumental Activities of Daily Living, Neuropsychiatric Symptoms, and Neuropsychological Impairment in Mild Cognitive Impairment. J Am Osteopath Assoc. 2019 Feb 1;119(2):96-101. doi: 10.7556/jaoa.2019.015.</citation>
    <PMID>30688355</PMID>
  </reference>
  <reference>
    <citation>Pita Fernández, S., Pértega Díaz, S., Unidad de Epidemiología Clínica y Bioestadística. Complexo Hospitalario Universitario de A Coruña (España) CAD ATEN PRIMARIA 2001; 8: 191-195</citation>
  </reference>
  <reference>
    <citation>Hanchi H, Mottawea W, Sebei K, Hammami R. The Genus Enterococcus: Between Probiotic Potential and Safety Concerns-An Update. Front Microbiol. 2018 Aug 3;9:1791. doi: 10.3389/fmicb.2018.01791. eCollection 2018.</citation>
    <PMID>30123208</PMID>
  </reference>
  <reference>
    <citation>Aguirre Leuke, Probióticos, prebióticos y simbióticos. El farmacéitico. 2017;542 pp. 25- 24</citation>
  </reference>
  <reference>
    <citation>Shi Y, Zhai M, Li J, Li B. Evaluation of safety and probiotic properties of a strain of Enterococcus faecium isolated from chicken bile. J Food Sci Technol. 2020 Feb;57(2):578-587. doi: 10.1007/s13197-019-04089-7. Epub 2019 Sep 11.</citation>
    <PMID>32116367</PMID>
  </reference>
  <reference>
    <citation>Rogers GB, Keating DJ, Young RL, Wong ML, Licinio J, Wesselingh S. From gut dysbiosis to altered brain function and mental illness: mechanisms and pathways. Mol Psychiatry. 2016 Jun;21(6):738-48. doi: 10.1038/mp.2016.50. Epub 2016 Apr 19.</citation>
    <PMID>27090305</PMID>
  </reference>
  <verification_date>January 2023</verification_date>
  <study_first_submitted>August 19, 2022</study_first_submitted>
  <study_first_submitted_qc>January 16, 2023</study_first_submitted_qc>
  <study_first_posted type="Actual">January 18, 2023</study_first_posted>
  <last_update_submitted>January 16, 2023</last_update_submitted>
  <last_update_submitted_qc>January 16, 2023</last_update_submitted_qc>
  <last_update_posted type="Actual">January 18, 2023</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Anahuac University</investigator_affiliation>
    <investigator_full_name>Jose Juan Antonio Ibarra Arias</investigator_full_name>
    <investigator_title>Responsable</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cognitive Dysfunction</mesh_term>
  </condition_browse>
  <study_docs>
    <study_doc>
      <doc_type>Study Protocol</doc_type>
      <doc_url>https://drive.google.com/drive/u/0/folders/1JG22lkEchQULxW79ktlsVcM5uGNB4iVh</doc_url>
    </study_doc>
  </study_docs>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

